-
Mashup Score: 13Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia | Blood | American Society of Hematology - 3 year(s) ago
Patients with chronic lymphocytic leukemia (CLL) have been previously shown to have poor responses to antibacterial and antiviral vaccines. In a Plenary Paper t
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia | Blood | American Society of Hematology - 3 year(s) ago
Patients with chronic lymphocytic leukemia (CLL) have been previously shown to have poor responses to antibacterial and antiviral vaccines. In a Plenary Paper t
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Efficacy of @BioNTech_Group @pfizer BNT162b2 mRNA #COVIDVaccine in Pts w/ CLL [6/10/21] @herishanu et al @BloodJournal https://t.co/FDK9EzcZ46 #NCT04746092 #COVID19nCancer #CLLsm #leusm #CCC19 #COVID19 @COVID19nCCC Ab response: Remission 79.2%; Tx-naive 55.2%; Active Tx 16.0% https://t.co/GdqDYKoEPC
-
-
Mashup Score: 13Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia | Blood | American Society of Hematology - 3 year(s) ago
Patients with chronic lymphocytic leukemia (CLL) have been previously shown to have poor responses to antibacterial and antiviral vaccines. In a Plenary Paper t
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Efficacy of @BioNTech_Group @pfizer BNT162b2 mRNA #COVIDVaccine in Pts w/ CLL [6/10/21] @herishanu et al @BloodJournal https://t.co/FDK9EzcZ46 #NCT04746092 #COVID19nCancer #CLLsm #leusm #CCC19 #COVID19 @COVID19nCCC Ab response: Remission 79.2%; Tx-naive 55.2%; Active Tx 16.0% https://t.co/uVERNAHXxK
-
-
Mashup Score: 2Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia | Blood | American Society of Hematology - 3 year(s) ago
Patients with chronic lymphocytic leukemia (CLL) have been previously shown to have poor responses to antibacterial and antiviral vaccines. In a Plenary Paper t
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia [Jun 10, 2021] @herishanu et al. @BloodJournal https://t.co/FDK9EzcZ46 #NCT04746092 #COVID19nCancer #COVIDVaccine #CLLsm #leusm #CCC19 #COVID19 @COVID19nCCC HT @CyclingDoctor
-
-
Mashup Score: 0Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia | Blood | American Society of Hematology - 3 year(s) ago
Key Points. Antibody response to BNT162b2 mRNA COVID-19 vaccine in patients with CLL is markedly impaired and affected by disease activity and treatment.In pati
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Efficacy of @BioNTech_Group @pfizer BNT162b2 mRNA #COVIDVaccine in Pts w/ CLL [6/10/21] @herishanu et al @BloodJournal https://t.co/FDK9EzcZ46 #NCT04746092 #COVID19nCancer #CLLsm #leusm #CCC19 #COVID19 @COVID19nCCC Ab response: Remission 79.2%; Tx-naive 55.2%; Active Tx 16.0% https://t.co/cYSoTxiKzQ
-
-
Mashup Score: 3Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia | Blood | American Society of Hematology - 3 year(s) ago
Key Points. Antibody response to BNT162b2 mRNA COVID-19 vaccine in patients with CLL is markedly impaired and affected by disease activity and treatment.In pati
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Efficacy of @BioNTech_Group @pfizer BNT162b2 mRNA #COVIDVaccine in Pts w/ CLL [6/10/21] @herishanu et al @BloodJournal https://t.co/FDK9EzcZ46 #NCT04746092 #COVID19nCancer #CLLsm #leusm #CCC19 #COVID19 @COVID19nCCC Ab response: Remission 79.2%; Tx-naive 55.2%; Active Tx 16.0% https://t.co/TUhc0xpArE
-
-
Mashup Score: 1Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia | Blood | American Society of Hematology - 3 year(s) ago
Key Points. Antibody response to BNT162b2 mRNA COVID-19 vaccine in patients with CLL is markedly impaired and affected by disease activity and treatment.In pati
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Efficacy of @BioNTech_Group @pfizer BNT162b2 mRNA #COVIDVaccine in Pts w/ CLL [6/10/21] @herishanu et al @BloodJournal https://t.co/FDK9EzcZ46 #NCT04746092 #COVID19nCancer #CLLsm #leusm #CCC19 #COVID19 @COVID19nCCC Ab response markedly impaired & affected by disease activity & Tx https://t.co/TTPl16tZkq
-
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia [Jun 10, 2021] @herishanu et al. @BloodJournal https://t.co/FDK9EzcZ46 #NCT04746092 #COVID19nCancer #COVIDVaccine #CLLsm #leusm #CCC19 #COVID19 @COVID19nCCC HT @CyclingDoctor https://t.co/BJUXjwGBdq
-
Efficacy of @BioNTech_Group @pfizer BNT162b2 mRNA #COVIDVaccine in Pts w/ CLL [6/10/21] @herishanu et al @BloodJournal https://t.co/FDK9EzcZ46 #NCT04746092 #COVID19nCancer #CLLsm #leusm #CCC19 #COVID19 @COVID19nCCC Ab response: Remission 79.2%; Tx-naive 55.2%; Active Tx 16.0% https://t.co/ibHV03HfQI